Guideline on Preparation and Quality Control of Tumor-Infiltrating Lymphocyte (TIL) Products Officially Released; Xunsheng Medicine Drives New Breakthrough in Cell and Gene Therapy Industry

On July 12, 2025, to help companies in the industry quickly align with international cutting-edge technology standards, the China Pharmaceutical Biotechnology Association and the Daxing Biomedical Industry Base Management Committee of Zhongguancun Science Park jointly hosted the release ceremony of the "Guidelines for the Preparation and Quality Control of Tumor-Infiltrating Lymphocyte (TIL) Formulations" and the key technology training course for tumor-infiltrating lymphocytes.

Zhao Beihai, Secretary General of the Chinese Association of Medical Biotechnology, Zhang Yonghong, Vice President of Beijing You'an Hospital, Wang Yuedan, Professor of Immunology at Peking University Health Science Center, Ding Xianping, Professor of Genetics at Sichuan University and Academician of the European Academy of Sciences, Song Changxing, President of Beidaihe Hospital, renowned experts from the PLA General Hospital and the Tumor Hospital Affiliated to Harbin Medical University, as well as Zhang Xiujun, President of Aeonvital, and He Zhou, Director of Shanghai Junsai Biotechnology Co., Ltd., attended this conference. Cao Zeyi, former Deputy Minister of Health of China, sent a video speech.

Zhao Beihai stated in his speech that the China Association for Medical Biotechnology will continue to play its role as a bridge and link. Through policy research, academic exchange, standard formulation, and other work, and by taking the opportunity of guideline release, promotion, and training, it will ensure the high-quality development of TIL technology and the biopharmaceutical industry.

Cao Zeyi pointed out in his speech that TIL therapy provides a new treatment approach for patients with advanced solid tumors who cannot tolerate traditional radiotherapy and chemotherapy, while also improving their quality of life. According to international standard treatment protocols, cervical cancer patients need to undergo hysterectomy, but TIL therapy offers the possibility for young female patients with cervical cancer to preserve their uterus during treatment. This makes a positive contribution to women's health and family well-being in China, as well as to the high-quality development and construction of China's population.

Deputy General Manager of Daxing Biomedical Industry Base CompanyLi Haitao said in his speech that Daxing Biomedical Base will always serve as a "servant" and "escort," providing the best policies, optimal supporting facilities, and the most practical services to support project implementation and achievement transformation. Together with the representatives attending the meeting, they will jointly build an innovative cell therapy industry cluster.

During this event, the "Guidelines for the Preparation and Quality Control of Tumor-Infiltrating Lymphocyte (TIL) Formulations" was officially released, marking a solid step forward in the standardized development of the TIL field in China. This will help the cell and gene therapy industry achieve new breakthroughs.

This guideline, which embodies the wisdom and hard work of numerous experts and scholars, will provide standards and norms for the preparation and quality control of TIL formulations, significantly enhancing the safety and efficacy of TIL technology in clinical applications. Aeonvital is one of the two companies that participated in drafting this guideline, contributing to the strengthening of the cell therapy industry at Daxing Biomedical Pharmaceutical Base.

At the same time as the aforementioned guidelines were released, a key technology training course for tumor-infiltrating lymphocytes (TIL) was successfully held. This training course focused on the core aspects of TIL technology, inviting well-known experts in China to provide systematic lectures and hands-on guidance. It aimed to help enterprises in the park quickly align with international cutting-edge technical standards, enhancing the R&D efficiency and industrialization capabilities of TIL therapeutic products.

It is reported that Aeonvital, with a core focus on tumor immunotherapy research, is dedicated to developing novel personalized tumor immunotherapy products. Its main R&D pipelines include Re-TIL tumor cell immunotherapy and HPV therapeutic nucleic acid vaccines. Relying on the founder's years of fundamental research achievements and knowledge reserves, the company combines neoantigen nucleic acid technology with cell therapy to comprehensively activate the immune system, accelerating the development of breakthrough solutions for curing cancer.